Second-Line Treatment of HER2+ mBC and Recent Data Updates


Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).

Related Videos
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Samilia Obeng-Gyasi, MD, MPH,
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Nan Chen, MD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"